CervoMed to Attend September Investor Conferences
CervoMed Inc. announces management participation in key investor conferences during September, discussing its clinical-stage work on age-related brain disorders and neflamapimod.
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (“CervoMed” or the “Company”), today announced that Company management will participate in the following investor conferences during the month of September:
Cantor Global Healthcare Conference
Format: Fireside Chat & 1×1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET
H.C. Wainwright Global Investment Conference
Format: Presentation & 1×1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET
Webcast Link:
https://journey.ct.events/view/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Contacts:
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
